CBLI

Cytocom, Inc. [CBLI] Stock Forecast

Q: What is Cytocom, Inc. stock symbol ?

Cytocom, Inc. is a US stock, located in Buffalo of New york and trading under the symbol CBLI

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

CBLI Stock Summary

EPS has been increasing for the past 3 years (Yearly statements)

Earnings are expected to fall -100% next year

CBLI has less than 1 year of cash runway

An RSI reading of 30 or below indicates an oversold or undervalued condition.

In the News

11:22 10 Jun 2023 CBLI

Cytocom, Inc. (CBLI) CEO Michael Handley on Q2 2021 Results - Earnings Call Transcript

07:30 10 Jun 2023 CBLI

Cytocom, Inc. Reports Second Quarter 2021 Financial Results

FORT COLLINS, Colo., Aug. 16, 2021 /PRNewswire/ -- Cytocom, Inc. (Nasdaq: CBLI), a leading biopharmaceutical company creating next-generation immune therapies for serious medical conditions that induce immune restoration and homeostasis, today reported recent corporate updates and financial results for the Company for the second quarter ended June 30, 2021, a period of time prior to the completion of the merger between legacy Cleveland BioLabs and the formerly private Cytocom Inc. Following the completion of the merger on July 27, 2021, Cytocom, Inc. emerged as a publicly traded entity.

07:30 10 Jun 2023 CBLI

Cytocom, Inc. Announces Participation at Liberty University's Empowering the Kingdom Through Business Conference

FORT COLLINS, Colo., Aug. 11, 2021 /PRNewswire/ -- Cytocom, Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that the company will participate at the Empowering the Kingdom through Business Conference hosted by the Liberty University School of Business on August 10-12, 2021.

07:30 10 Jun 2023 CBLI

Cytocom, Inc. to Report Second Quarter 2021 Financial Results

FORT COLLINS, Colo., Aug. 10, 2021 /PRNewswire/ -- Cytocom, Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that the Company will host a conference call and live audio webcast on Monday, August 16, 2021, at 8:30 a.m.

07:30 10 Jun 2023 CBLI

Cytocom Inc. Provides Updates on Key Clinical Programs for Crohn's Disease, Hematology, Pancreatic Cancer and COVID-19

FORT COLLINS, Colo., Aug. 9, 2021 /PRNewswire/ -- Cytocom Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today provided an update regarding its portfolio of clinical programs.

07:33 10 Jun 2023 CBLI

Cytocom Inc. Provides Update on Completed Merger with Cleveland BioLabs

FORT COLLINS, Colo., Aug. 5, 2021 /PRNewswire/ -- Cytocom Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today provided shareholders with an update regarding its recent merger with Cleveland BioLabs.

07:33 10 Jun 2023 CBLI

Cytocom, Inc. Receives Commitments for $90 Million in Equity and Debt Financing

FORT COLLINS, Colo., July 29, 2021 /PRNewswire/ -- Cytocom, Inc., (NASDAQ: CBLI), a leading biopharmaceutical company developing next generation therapies that focus on immune homeostasis, has secured agreements for $90 million in committed capital.

09:16 10 Jun 2023 CBLI

Cleveland BioLabs, Inc. and Cytocom Inc. Announce Call to Discuss Stockholder Meeting Vote Results and Proposed Merger

FORT COLLINS, Colo. and BUFFALO, N.Y.

05:58 10 Jun 2023 CBLI

CBLI Stock Price Increases Over 15% Pre-Market: Why It Happened

The stock price of Cleveland BioLabs, Inc. (Nasdaq: CBLI) increased by over 15% pre-market. This is why it happened.

06:37 10 Jun 2023 CBLI

Cleveland BioLabs, Inc. and Cytocom Announce Registration Statement and Proxy Statement for Previously Announced Merger Declared Effective by SEC

FORT COLLINS, Colo. and BUFFALO, N.Y.

CBLI Financial details

Company Rating

Buy

Market Cap

226.39M

Income

-2.64M

Revenue

43.65K

Book val./share

0.87

Cash/share

0.89

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

16 Aug 2021

P/E

-16.38

Forward P/E

PEG

11.09

P/S

10673292000.65

P/B

19.52

P/C

3.56

P/FCF

-95.4

Quick Ratio

7.49

Current Ratio

7.6

Debt / Equity

0.02

LT Debt / Equity

EPS (TTM)

-0.2

EPS next Y

EPS next Q

EPS this Y

-17.39%

EPS next Y

EPS next 5Y

EPS last 5Y

-4.56%

Revenue last 5Y

-40.47%

Revenue Q/Q

EPS Q/Q

6.52%

SMA20

SMA50

SMA100

Inst Own

Inst Trans

ROA

-103%

ROE

-160%

ROC

-1.28%

Gross Margin

Oper. Margin

-984%

Profit Margin

-912%

Payout

Shs Outstand

71.42M

Shs Float

47.55M

Target Price

52W Range

3.11-3.5

52W High

+5.67%

52W Low

+5.67%

RSI

Rel Volume

0.74

Avg Volume

156.95K

Volume

116.26K

Perf Week

10466.67%

Perf Month

3422.22%

Perf Quarter

Perf Half Y

Beta

0.683695

Volatility

1.1%, 0.56%

Prev Close

11141.13%

Price

3.17

Change

10756.16%

CBLI Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2020-12-31

Metric	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31
Revenue per share	0.32	0.17	0.1	0.1	0.02
Net income per share	-0.24	-0.87	-0.32	-0.23	-0.19
Operating cash flow per share	-0.46	-0.59	-0.41	-0.24	-0.19
Free cash flow per share	-0.46	-0.59	-0.41	-0.24	-0.19
Cash per share	1.39	0.79	0.36	0.14	0.18
Book value per share	1.17	0.66	0.32	0.09	0.16
Tangible book value per share	1.17	0.66	0.32	0.09	0.16
Share holders equity per share	1.17	0.66	0.32	0.09	0.16
Interest debt per share	0	0	0	0	0.21
Market cap	15.6M	44.88M	11.41M	6.8M	42.77M
Enterprise value	8.7M	40.65M	7.79M	5.68M	40.82M
P/E ratio	-5.87	-4.62	-3.16	-2.57	-17.83
Price to sales ratio	4.43	23.04	10.02	6.11	162.65
POCF ratio	-3.1	-6.79	-2.47	-2.55	-18.02
PFCF ratio	-3.09	-6.78	-2.46	-2.55	-18.02
P/B Ratio	1.21	6.06	3.16	6.91	21.24
PTB ratio	1.21	6.06	3.16	6.91	21.24
EV to sales	2.47	20.86	6.84	5.1	155.25
Enterprise value over EBITDA	-3.35	-4.2	-2.17	-2.16	-17.1
EV to operating cash flow	-1.73	-6.15	-1.69	-2.13	-17.2
EV to free cash flow	-1.72	-6.14	-1.68	-2.13	-17.2
Earnings yield	-0.17	-0.22	-0.32	-0.39	-0.06
Free cash flow yield	-0.32	-0.15	-0.41	-0.39	-0.06
Debt to equity	0.24	0.3	0.25	1.07	0.15
Debt to assets	0.19	0.23	0.2	0.52	0.13
Net debt to EBITDA	2.66	0.44	1.01	0.43	0.82
Current ratio	5.11	4.33	4.91	1.9	7.6
Interest coverage	0	0	0	0	0
Income quality	1.9	0.68	1.28	1.01	0.99
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.96	1.28	2.04	1.63	8.21
Research and developement to revenue	1.85	2.59	3.18	1.49	2.63
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0	0	0.01	0	0
Capex to revenue	0	0	-0.02	0	0
Capex to depreciation	-0.16	-0.21	-1.53	-0.11	0
Stock based compensation to revenue	0	0	0	0	0.05
Graham number	2.52	3.59	1.52	0.68	0.84
ROIC	-3.5	-5.79	1.69	4.93	1.48
Return on tangible assets	-0.17	-1.01	-0.8	-1.3	-1.03
Graham Net	1.13	0.62	0.3	0.07	0.16
Working capital	12.78M	7.37M	3.56M	950.11K	2.01M
Tangible asset value	12.85M	7.41M	3.61M	984.29K	2.01M
Net current asset value	12.78M	7.36M	3.56M	950.11K	2.01M
Invested capital	0	0	0	0	1.31
Average receivables	491.89K	453.58K	403.16K	315.36K	195.19K
Average payables	266.78K	268.92K	170.26K	201.35K	215.67K
Average inventory	0	0	0	0	0
Days sales outstanding	36.59	103.87	80.76	124.2	15.98
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	9.98	3.51	4.52	2.94	22.84
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-0.21	-1.31	-1	-2.69	-1.19
Capex per share	0	0	0	0	0

Quarterly Fundamentals Overview

Last date of statement is 2021-06-30 for Q2

Metric	2020-06-30	2020-09-30	2020-12-31	2021-03-31	2021-06-30
Revenue per share	0.01	0	0	0	0
Net income per share	-0.03	-0.06	-0.05	-0.04	-0.04
Operating cash flow per share	-0.04	-0.05	-0.06	-0.03	-0.06
Free cash flow per share	-0.04	-0.05	-0.06	-0.03	-0.06
Cash per share	0.32	0.23	0.17	1.03	0.89
Book value per share	0.28	0.21	0.15	0.65	0.87
Tangible book value per share	0.28	0.21	0.15	1	0.87
Share holders equity per share	0.28	0.21	0.15	0.65	0.87
Interest debt per share	0	0	0.16	0	0
Market cap	30.7M	25.61M	44.86M	74.69M	84.67M
Enterprise value	27.3M	22.89M	42.91M	60.33M	70.89M
P/E ratio	-20.76	-8.59	-16.14	-34.7	-32.1
Price to sales ratio	485.41	586.89	170602.11B	0	0
POCF ratio	-64.45	-37.52	-56.9	-205.71	-98.4
PFCF ratio	-64.45	-37.52	-56.9	-205.71	-98.4
P/B Ratio	9.33	9.32	22.28	8.1	6.26
PTB ratio	9.33	9.32	22.28	8.1	6.26
EV to sales	431.51	524.54	163199.65B	0	0
Enterprise value over EBITDA	-74.38	-30.95	-62.01	-112.52	-107.69
EV to operating cash flow	-57.29	-33.54	-54.43	-166.16	-82.39
EV to free cash flow	-57.29	-33.54	-54.43	-166.16	-82.39
Earnings yield	-0.01	-0.03	-0.02	-0.01	-0.01
Free cash flow yield	-0.02	-0.03	-0.02	0	-0.01
Debt to equity	0.24	0.18	0.15	0.06	0.02
Debt to assets	0.19	0.15	0.13	0.04	0.02
Net debt to EBITDA	9.29	3.68	2.81	26.78	20.93
Current ratio	5.17	6.66	7.6	28.36	45.98
Interest coverage	0	-272.79	0	0	0
Income quality	1.29	0.92	1.13	0.67	1.3
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	7.67	16.01	2251.15B	0	0
Research and developement to revenue	2.69	2.7	703.62B	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0	0	0	0	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	0	0	0	0	0
Stock based compensation to revenue	0	0.31	0	0	0
Graham number	0.44	0.52	0.43	0.74	0.92
ROIC	0.19	0.31	0.45	0.04	0.05
Return on tangible assets	-0.09	-0.23	-0.3	-0.04	-0.05
Graham Net	0.26	0.2	0.15	0.99	0.87
Working capital	3.28M	2.74M	2.01M	14.18M	13.52M
Tangible asset value	3.29M	2.75M	2.01M	14.18M	13.53M
Net current asset value	3.28M	2.74M	2.01M	14.18M	13.52M
Invested capital	0	0	1.06	0	0
Average receivables	290.49K	190.88K	73.36K	5.76K	0
Average payables	283.84K	291.09K	224.17K	238.75K	185.11K
Average inventory	0	0	0	0	0
Days sales outstanding	350.8	278.81	3940.34B	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0.26	0.32	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-0.11	-0.27	-0.35	-0.06	-0.05
Capex per share	0	0	0	0	0

CBLI Frequently Asked Questions

What is Cytocom, Inc. stock symbol ?

Cytocom, Inc. is a US stock , located in Buffalo of New york and trading under the symbol CBLI

What is Cytocom, Inc. stock quote today ?

Cytocom, Inc. stock price is $3.17 today.

Is Cytocom, Inc. stock public?

Yes, Cytocom, Inc. is a publicly traded company.

Something similar

Top by Market Cap

BRH.DE

AAPL

AMZN

Company Profile

Volume Average 156.95K
Market Capitalization 226.39M
Employee 18
CEO Dr. Yakov Kogan
Headquarters Buffalo,NEW YORK,US
IPO Date 2006-07-21
Website http://www.cytocom.com

Cleveland BioLabs, Inc. operates as a biopharmaceutical company, which engages in the research and development of drugs. The company is headquartered in Buffalo, New York and currently employs 15 full-time employees. The firm is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications. Its other products include CBLB612, Mobilan and CBL0137. CBLB612 is a compound based upon a natural activator of another tissue-specific component of the innate immune system, the toll-like receptor 2 (TLR2)/ toll-like receptor 6 (TLR6) heterodimeric receptor. Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. CBL0137 is a small molecule with a multi-targeted mechanism of action that may be useful for the treatment of various types of cancer.